Account
Insider Insights
30.01.2024
NICE recommends Talazoparib for advanced breast ca...

NICE set to endorse talazoparib for adults with BRCA 1 or 2 mutated HER2-negative locally advanced o...

Read more
News
16.11.2023
ISPOR Europe 2023

We're thrilled to announce our participation at ISPOR Europe 2023 in Copenhagen this November. We'll...

Read more
Publications
25.10.2023
ISPOR Europe 2023: Can Just Three PICOs be Feasibl...

This research aims to understand if just three PICOs are feasible by analysing recent HTA assessment...

Read more
Articles
21.06.2023
What are the current unmet needs in Oncology?

We explore the innovative assessment criteria for novel cancer therapies and the unmet needs in onco...

Read more
Insider Insights
13.06.2023
Collaboration proposes a new method for combinatio...

In a joint report Lif, the New Therapeutics (NT) Council and representatives of the regions have pro...

Read more
Articles
09.06.2023
What is a fair value for oncology combination pric...

We explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...

Read more
News
07.06.2023
PMA Insights: Week 23

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
News
02.02.2023
PMA Insights: Week 5

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
02.02.2023
NICE has recommended Yescarta as the first CAR T-c...

NICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...

Read more
Case Study
01.01.2023
Developing scenario-based commercial assessments

Identification of current cost of oncology care treatment options.

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.